U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H20F2N4O2
Molecular Weight 410.4166
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEMBOREXANT

SMILES

CC1=NC=C(OC[C@]2(C[C@H]2C(=O)NC3=NC=C(F)C=C3)C4=CC=CC(F)=C4)C(C)=N1

InChI

InChIKey=MUGXRYIUWFITCP-PGRDOPGGSA-N
InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H20F2N4O2
Molecular Weight 410.4166
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:45:47 UTC 2023
Edited
by admin
on Fri Dec 15 16:45:47 UTC 2023
Record UNII
0K5743G68X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEMBOREXANT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
LEMBOREXANT [JAN]
Common Name English
DAYVIGO
Brand Name English
(1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide
Systematic Name English
(1R,2S)-2-((2,4-DIMETHYLPYRIMIDIN-5-YL)OXYMETHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL)CYCLOPROPANE-1-CARBOXAMIDE
Systematic Name English
LEMBOREXANT [ORANGE BOOK]
Common Name English
Lemborexant [WHO-DD]
Common Name English
CYCLOPROPANECARBOXAMIDE, 2-(((2,4-DIMETHYL-5-PYRIMIDINYL)OXY)METHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-, (1R,2S)-
Systematic Name English
LEMBOREXANT [MI]
Common Name English
E2006
Code English
lemborexant [INN]
Common Name English
E-2006
Code English
LEMBOREXANT [USAN]
Common Name English
Classification Tree Code System Code
DEA NO. 2245
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
Code System Code Type Description
INN
9988
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
DAILYMED
0K5743G68X
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
EPA CompTox
DTXSID401027940
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
RXCUI
2272403
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
ChEMBL
CHEMBL3545367
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
FDA UNII
0K5743G68X
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
CAS
1369764-02-2
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
SMS_ID
100000175741
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
USAN
CD-24
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
LACTMED
Lemborexant
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
DRUG CENTRAL
5360
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
DRUG BANK
DB11951
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
WIKIPEDIA
Lemborexant
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
NCI_THESAURUS
C166424
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
MERCK INDEX
m12187
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
PUBCHEM
56944144
Created by admin on Fri Dec 15 16:45:47 UTC 2023 , Edited by admin on Fri Dec 15 16:45:47 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Structure of LEMBOREXANT
EXCRETED UNCHANGED
URINE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
Protein binding of lemborexant is approximately 93.2% to 94.0% between 29 ng/mL and 71 ng/mL.
BINDING
CYTOCHROME P450 2B6
METABOLIC ENZYME -> INDUCER
CYTOCHROME P450 2A6
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE INHIBITION
IC50
OREXIN RECEPTOR TYPE 2
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INDUCER
OREXIN RECEPTOR TYPE 1
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INHIBITOR
REVERSIBLE INHIBITION
IC50
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
WEAK
TIME-DEPENDENT INHIBITION
Ki
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
MINOR
Related Record Type Details
Structure of 2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-2-(((4-(HYDROXYMETHYL)-2-METHYL-5-PYRIMIDINYL)OXY)METHYL)CYCLOPROPANECARBOXAMIDE, (1R,2S)-
METABOLITE -> PARENT
PLASMA
Structure of CYCLOPROPANECARBOXAMIDE, 2-(((2,4-DIMETHYL-5-PYRIMIDINYL)OXY)METHYL)-2-(5-FLUORO-2-HYDROXYPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-, (1R,2S)-
METABOLITE -> PARENT
PLASMA
Structure of CYCLOPROPANECARBOXAMIDE, 2-(((2,4-DIMETHYL-1-OXIDO-5-PYRIMIDINYL)OXY)METHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-, (1R,2S)-
METABOLITE -> PARENT
PLASMA
Structure of CYCLOPROPANECARBOXAMIDE, 2-(((2,6-DIMETHYL-1-OXIDO-5-PYRIMIDINYL)OXY)METHYL)-2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-, (1R,2S)-
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of CYCLOPROPANECARBOXAMIDE, 2-(3-FLUOROPHENYL)-N-(5-FLUORO-2-PYRIDINYL)-2-(((2-(HYDROXYMETHYL)-4-METHYL-5-PYRIMIDINYL)OXY)METHYL)-, (1R,2S)-
METABOLITE -> PARENT
PLASMA
Related Record Type Details
Structure of LEMBOREXANT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

Tmax PHARMACOKINETIC HIGH-FAT AND HIGH-CALORIE MEAL

FED CONDITION

Tmax PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966